Drug Trial Radar · NCT05389267
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
Last checked: Nov 20, 2026Latest source record: Feb 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jul 5, 2022
Primary completion
Dec 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Laboratoires TheaIndustry
- Sponsor type
- Industry
- First posted
- May 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study purpose is to evaluate the safety of T4090.
Conditions
- Glaucoma
- Ocular Hypertension
Interventions
Kinezodianone R hydrochlorideDrug
Eyedrops
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ocular and systemic adverse eventsTime frame: up to 22 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dr EL-HARAZI
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.